Current view on hepatitis B diagnosis and therapy

Czech version

Authors: Petr Husa
Authors‘ workplace: Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice
Published in: Vnitř Lék 2021; 67(1): 48-50
Category:

Overview

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors predominantly vaccination policy and migration. Chronic hepatitis B is a dynamic process reflecting the interaction between HBV replication and the host immune response and not all patients with chronic HBV infection have chronic hepatitis B. Stopping of nucleotide or nucleoside analogues (NA) therapy is a serious resolution due the danger of reactivation of viral replication associated with increasing HBV DNA level, ALT activity and inflammatory activity in the liver histology. The safest stopping rule for NA therapy is HBsAg loss what is the sign of immune control of HBV infection.

Keywords:

chronic hepatitis B – tenofovir – entecavir – stopping therapy.

Sources

1. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017, http://dx.doi.org/10.1016/j.hep.2017. 03. 021.

2. AASLD guidelines for treatment of chronic hepatitis B. Datum vydání: listopad 2015. Dostupné na: https://www.aasld.org/sites/default/files/2019-06/Terrault_et_al-2016-Hepatology.pdf.

3. Asian‑Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10 : 1–98.

4. Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Gastroent Hepatol 2017; 71(5) : 419–437.

5. Husa P, Šperl J, Urbánek P, Fraňková S, Plíšek S, Kümpel P, Rožnovský L. Doporučený postup diagnostiky a léčby infekce virem hepatitidy B. Datum vydání doporučení: září 2017. Klin mikrobiol inf lek 2017; 23(4): 148–164.

6. Brown SR. Hepatitis now: defining optimal treatment duration in HBV. Clinical Care Options. Dostupné na: https://www.clinicaloptions.com/hepatitis/programs/hepatitisnow2019/optimal‑hbv‑treatment‑duration/slides-2